Holistic approach for molecules' identification and optimisation for an effective drug discovery workflow
Healthcare Data analyses using state-of-the-art AI technologies for compounds' hit-to-lead generation and lead optimization for drug discovery
How can we help you?
Aomics GmbH is a German based company, specialized in the area of drug discovery and drug target identification. By leveraging state-of-the-art artificial intelligence, multi-omics and cheminformatic techniques, we efficiently reduce the time and cost of the drug development process to several folds.
- Identification of novel molecular drug targets using multi-omics data
- Use AI to identify the existing knowledge on these variations from our in-house databases
- In-silico prediction of existing FDA/EMA approved drugs/small-molecules that could be re-positioned for the indication of interest
- Perform de-novo based novel drug-target identification and use the existing/generated multi-omics data .
Would you like to start a project with us?
Reach out on the given number or write us an email for further queries regarding project requirements